Latest Information Update: 14 Apr 2016
At a glance
- Originator Amgen
- Class Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dyslipidaemias
Most Recent Events
- 16 Feb 2016 Phase-II clinical trials in Dyslipidaemias in USA (unspecified route) before February 2016